Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Post by jermiah777on Aug 09, 2021 12:13pm
140 Views
Post# 33672127

1/3 owned by directors/insiders

1/3 owned by directors/insidersSo I believe the web-site says management and insiders own about 1/3 of shares. So a big pharmaceutical company only needs 51% to own Willow. Or so 60 million shares x 80 cents is 48 million. So imagine that: for 48 million you could possibly buy half of Willow and be the owner. You now control the 41 million they have in cash. And all their intellectual property. All profits they make you get half. All on one condition: that you can buy 60 million shares of Willow for the price of 80 cents or less. I know this is way to simplistic but an analyst a year ago did say they see Willow as a possible target for a takeover. Maybe we can hope Canopy or some big pharmaceutical company buys them out.
<< Previous
Bullboard Posts
Next >>